跳至主要内容
临床试验/NL-OMON49852
NL-OMON49852撤回不适用

Modified Exclusive Enteral Nutrition with the Crohn's Disease Exclusion Diet for Induction and Maintenance of Remission and Re-biosis - DIETOMICS

Academisch Medisch Centrum0 个研究点目标入组 35 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
入组人数
35

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 99(—)

入选标准

  • For Patients
  • 1. Established diagnosis of Crohn's disease.
  • 2. Patients with mild to severe active Crohn's disease (15*PCDAI*47.5)
  • 3. Ages 8-18
  • 4. Duration of disease * 36 months
  • 5. Active inflammation (CRP*0.6 mg/dL or ESR*20 or Calprotectin*200 mcg/gr
  • during screening
  • 6. Patients with B1, P0 uncomplicated disease at enrollment
  • 7. Patients with disease defined as L1, L4, L3 or L2 limited to cecum,
  • ascending or transverse colon or L2 with left sided disease with terminal ileum
  • or small bowel involvement in the past by the Paris classification (patients
  • with macroscopic disease)
  • 8. Signed informed consent
  • Inclusion criteria comments:
  • 1. Patients with stable medication (IMM/5ASA) use or no medication use for the
  • past 8 weeks may be enrolled.
  • 2. Patients with few aphthous ulcers in the rectosigmoid only can be enrolled

排除标准

  • For patients
  • 1. Patients with very mild disease (PCDAI 12.5-15) or very severe disease
  • (PCDAI >47.5)
  • 2. Pregnancy
  • 3. Patients who have disease confined to the colon involving the descending
  • colon, rectum or sigmoid colon and no prior history of small bowel involvement
  • 4. Patients who have active extra intestinal disease (such as arthritis,
  • uveitis, pyoderma gangresom, erythema nodosum, etc.)
  • 5. Patients with complicated disease (B2, B3)
  • 6. Patients with recent onset use of an immunomodulator <8 weeks, or dose
  • change in past 8 weeks.
  • 7. Patients with past or current use of biologics, or patients who currently
  • use systemic steroids or used steroids over the last 8 weeks
  • 8. Patients who have active perianal disease (active fistula or abscess)
  • 9. Patients who have positive stool cultures with relevant pathogens, or
  • positive tests for parasites or C. difficile. Stool tests are mandatory only if
  • diarrhea is present.
  • 10. Patients with fever > 38.3
  • 11. Documented milk protein allergy
  • Exclusion criteria comments:
  • 1. Aphthous stomatitis is not an exclusion criterion. Isolated aphthous ulcers
  • of the rectosigmoid need not be excluded as left sided L2 only
  • 2. Patient may receive a stable dose immunomodulator or start thiopurines at or
  • after week 4 or Methotrexate at week 6, since the effect of thiopurine starts
  • after 8 weeks and that does not affect the primary endpoint remission at week 8.
  • 3. Patients are allowed use of Omeprazole if ulcers or erosions are present in
  • the stomach or duodenum.
  • 4. Patients may receive antibiotics for intercurrent infections for up to 10
  • days with the exception of quinolones, metronidazole, rifaximin or oral
  • vancomycin; antibiotics used must be registered in the CRF.
  • 5. Patients with skin tags or fissures can be enrolled.

研究者

相似试验